Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3YH4I)

• Drug Name: D-Serine Drug Info
• Synonyms: D-serine; 312-84-5; (R)-2-amino-3-hydroxypropanoic acid; (2R)-2-amino-3-hydroxypropanoic acid; Serine D-form; (R)-Serine; Serine, D-; d-(+)-serine; D-2-Amino-3-hydroxypropionic Acid; D-Serin; D-Ser; UNII-1K77H2Z9B1; EINECS 206-229-4; MFCD00004269; NSC 77689; (2R)-2-amino-3-hydroxy-propanoic acid; AI3-18476; CHEMBL285123; CHEBI:16523; MTCFGRXMJLQNBG-UWTATZPHSA-N; 1K77H2Z9B1; (R)-2-Amino-3-hydroxypropionic acid; DSN; NCGC00094363-03; D-Serine, 98%; D-2-Amino-3-hydroxypropanoic acid; NSC77689; serine d-; [3h]-d-serine; (2R)-serine
• Cross-matching ID:
  PubChem CID: 71077
  ChEBI ID: CHEBI:16523
  CAS Number: CAS 312-84-5
  TTD Drug ID: DM3YH4I
  VARIDT Drug ID: DR00047
  INTEDE Drug ID: DR1922

Molecule-Related Drug Atlas

Drug(s) Targeting Strychnine-binding glycine receptor (GLRA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[5]
GINKOLIDE B	DMLIM7B	Sepsis	1G40-1G41	Terminated	[6]
3-demethoxy-3-D-lyxopyranosylaminothiocolchicine	DME8VPC	Discovery agent	N.A.	Investigative	[5]
3-demethoxy-3-D-xylopyranosylaminothiocolchicine	DMXFVD1	Discovery agent	N.A.	Investigative	[5]
3-demethoxy-3-L-fucopyranosylaminothiocolchicine	DM4ERYF	Discovery agent	N.A.	Investigative	[5]
3-demethoxy-3D-glucopyranosylaminothiocolchicine	DMID7TC	Discovery agent	N.A.	Investigative	[5]
3-demethoxy-3-D-mannopyranosylaminothiocolchicine	DMALMGH	Discovery agent	N.A.	Investigative	[5]
GINKGOLIDE A	DMKZJ7T	Discovery agent	N.A.	Investigative	[6]
Ginkgolide J	DMUOMP1	Discovery agent	N.A.	Investigative	[6]
Ginkgolide C	DMVN374	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Glutamate receptor ionotropic NMDA 1 (NMDAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[7]
ELIPRODIL	DMIOGZM	Multiple sclerosis	8A40	Phase 2	[8]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[9]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[10]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[11]
L-689560	DMCVY4U	Neurodegenerative disorder	8A20-8A23	Terminated	[12]
L-698544	DMLRBN1	Alzheimer disease	8A20	Terminated	[13]
DIZOCILPINE	DMMGYXR	Cerebrovascular ischaemia	8B1Z	Terminated	[14]
RPR-104632	DM9L50N	N. A.	N. A.	Terminated	[15]
L-698532	DMO9HM7	Neurological disorder	6B60	Terminated	[16]

Drug(s) Transported By Alanine/serine/cysteine/threonine transporter 1 (SLC1A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Alanine	DMZDN4W	Dietary shortage	5B5K	Approved	[2]

Drug(s) Transported By Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[17]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[17]
Levacecarnine hci	DMJBOCR	Cognitive impairment	6D71	Approved	[18]
Glycine	DMIOZ29	Allergic rhinitis	CA08.0	Approved	[19]
L-glutamine	DM69G8X	Short bowel syndrome	KB89.1	Approved	[20]
Valaciclovir	DMHKS94	Genital herpes	1A94	Approved	[21]
Valganciclovir	DMS2IUH	Virus infection	1A24-1D9Z	Approved	[22]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[23]
L-threonine	DMFHTBX	Discovery agent	N.A.	Investigative	[2]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor ionotropic NMDA 1 (NMDAR1)	TTLD29N	NMDZ1_HUMAN	Inhibitor	[1]
Strychnine-binding glycine receptor (GLRA1)	TTF45NW	GLRA1_HUMAN	Inhibitor	[1]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Alanine/serine/cysteine/threonine transporter 1 (SLC1A4)	DTC54PX	SATT_HUMAN	Substrate	[2]
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)	DTW7AE3	AAAT_HUMAN	Substrate	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
D-amino-acid oxidase (DAO)	DERZQ2Y	OXDA_HUMAN	Substrate	[3]
Serine racemase (SRR)	DEKOQX7	SRR_HUMAN	Substrate	[4]

References

• [1] Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
• [2] D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
• [3] Focus on the role of D-serine and D-amino acid oxidase in amyotrophic lateral sclerosis/motor neuron disease (ALS). Front Mol Biosci. 2018 Feb 13;5:8.
• [4] D-Serine made by serine racemase in Drosophila intestine plays a physiological role in sleep. Nat Commun. 2019 May 7;10(1):1986.
• [5] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [6] Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
• [7] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [8] 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
• [9] Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
• [10] 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
• [11] Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
• [13] Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
• [14] Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
• [15] Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
• [16] Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
• [17] Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
• [18] A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the blood-brain barrier. Biochem Biophys Res Commun. 2008 Nov 14;376(2):267-70.
• [19] Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G1046-53.
• [20] High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5.
• [21] Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther. 2004 Mar;308(3):1138-47.
• [22] Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10.
• [23] Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506.